Cencora Inc
NYSE:COR
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
224.68
374.75
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
COR
stock under the Base Case scenario is
538.35
USD.
Compared to the current market price of 342.96 USD,
Cencora Inc
is
Undervalued by 36%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Cencora Inc.
| US |
|
Mckesson Corp
NYSE:MCK
|
|
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
|
| US |
|
Cardinal Health Inc
NYSE:CAH
|
|
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
|
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
|
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
|
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
|
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
|
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
|
| AU |
E
|
EBOS Group Ltd
OTC:EBOSY
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Cencora’s continued exposure to opioid litigation and settlement expenses could weigh heavily on its profitability and drain resources from growth initiatives, especially if settlement costs surpass current estimates.
Ongoing downward pricing pressure from major clients—especially large pharmacy chains with increasing negotiating leverage—could squeeze Cencora’s already slim distribution margins and hamper revenue growth.
Aggressive global expansion through acquisitions and the new brand identity might stretch management’s focus and capital, leading to integration challenges or suboptimal returns on recent investments.
Cencora’s extensive distribution network and deep relationships with pharmaceutical manufacturers, including high-value specialty drug makers, position it to capture incremental demand as specialty pharmaceuticals gain market share.
The company’s shift toward offering value-added services, such as patient support and supply-chain consulting, enables higher-margin revenue streams and differentiates Cencora from pure-play distributors.
Cencora’s unified global branding and expansion strategy could strengthen its international positioning, open new markets for specialty distribution, and enhance the cross-selling of ancillary services across its worldwide footprint.
Revenue & Expenses Breakdown
Cencora Inc
Balance Sheet Decomposition
Cencora Inc
| Current Assets | 52.2B |
| Cash & Short-Term Investments | 4.4B |
| Receivables | 26.9B |
| Other Current Assets | 21B |
| Non-Current Assets | 24.4B |
| PP&E | 2.5B |
| Intangibles | 17.5B |
| Other Non-Current Assets | 4.4B |
| Current Liabilities | 57.8B |
| Accounts Payable | 54.7B |
| Accrued Liabilities | 3B |
| Other Current Liabilities | 117.8m |
| Non-Current Liabilities | 17.3B |
| Long-Term Debt | 7.5B |
| Other Non-Current Liabilities | 9.7B |
Free Cash Flow Analysis
Cencora Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Cencora Inc
|
Revenue
|
321.3B
USD
|
|
Cost of Revenue
|
-310B
USD
|
|
Gross Profit
|
11.3B
USD
|
|
Operating Expenses
|
-7.5B
USD
|
|
Operating Income
|
3.7B
USD
|
|
Other Expenses
|
-2.2B
USD
|
|
Net Income
|
1.6B
USD
|
COR Profitability Score
Profitability Due Diligence
Cencora Inc's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
Score
Cencora Inc's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
COR Solvency Score
Solvency Due Diligence
Cencora Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Score
Cencora Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
COR Price Targets Summary
Cencora Inc
According to Wall Street analysts, the average 1-year price target for
COR
is 391.08 USD
with a low forecast of 282 USD and a high forecast of 437.85 USD.
Dividends
Current shareholder yield for
COR is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
COR
stock under the Base Case scenario is
538.35
USD.
Compared to the current market price of 342.96 USD,
Cencora Inc
is
Undervalued by 36%.